Literature DB >> 18992837

Discovery of new Mycoplasma pneumoniae antigens by use of a whole-genome lambda display library.

Elisa Beghetto1, Francesca De Paolis, Francesca Montagnani, Carla Cellesi, Nicola Gargano.   

Abstract

Mycoplasma pneumoniae is the leading cause of atypical pneumonia in children and young adults. Bacterial colonization can occur in both the upper and the lower respiratory tracts and take place both endemically and epidemically worldwide. Characteristically, the infection is chronic in onset and recovery and both humoral and cell-mediated mechanisms are involved in the response to bacterial colonization. To identify bacterial proteins recognized by host antibody responses, a whole-genome M. pneumoniae library was created and displayed on lambda bacteriophage. The challenge of such a library with sera from individuals hospitalized for mycoplasmal pneumonia allowed the identification of a panel of recombinant bacteriophages carrying B-cell epitopes. Among the already known M. pneumoniae B-cell antigens, our results confirmed the immunogenicity of P1 and P30 adhesins. Also, the data presented in this study localized, within their sequences, the immunodominant epitopes recognized by human immunoglobulins. Furthermore, library screening allowed the identification of four novel immunogenic polypeptides, respectively, encoded by fragments of the MPN152, MPN426, MPN456 and MPN-500 open reading frames, highlighting and further confirming the potential of lambda display technology in antigen and epitope discovery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18992837     DOI: 10.1016/j.micinf.2008.10.004

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  10 in total

Review 1.  Phage display--a powerful technique for immunotherapy: 2. Vaccine delivery.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

2.  Strategy to create chimeric proteins derived from functional adhesin regions of Mycoplasma pneumoniae for vaccine development.

Authors:  Nicol Schurwanz; Enno Jacobs; Roger Dumke
Journal:  Infect Immun       Date:  2009-08-10       Impact factor: 3.441

3.  Use of recombinant chimeric antigens for the serodiagnosis of Mycoplasma pneumoniae infection.

Authors:  F Montagnani; F De Paolis; E Beghetto; N Gargano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-15       Impact factor: 3.267

4.  Proteomic Monitoring of B Cell Immunity.

Authors:  Radwa Ewaisha; Karen S Anderson
Journal:  Methods Mol Biol       Date:  2016

Review 5.  Antibody Response to Mycoplasma pneumoniae: Protection of Host and Influence on Outbreaks?

Authors:  Roger Dumke; Enno Jacobs
Journal:  Front Microbiol       Date:  2016-01-26       Impact factor: 5.640

Review 6.  Lambda-display: a powerful tool for antigen discovery.

Authors:  Elisa Beghetto; Nicola Gargano
Journal:  Molecules       Date:  2011-04-13       Impact factor: 4.411

Review 7.  Oligopeptide m13 phage display in pathogen research.

Authors:  Jonas Kügler; Jonas Zantow; Torsten Meyer; Michael Hust
Journal:  Viruses       Date:  2013-10-16       Impact factor: 5.048

8.  Delineation of immunodominant and cytadherence segment(s) of Mycoplasma pneumoniae P1 gene.

Authors:  Bishwanath K Chourasia; Rama Chaudhry; Pawan Malhotra
Journal:  BMC Microbiol       Date:  2014-04-28       Impact factor: 3.605

9.  Lipid moieties of Mycoplasma pneumoniae lipoproteins are the causative factor of vaccine-enhanced disease.

Authors:  Arlind B Mara; Tyler D Gavitt; Edan R Tulman; Steven J Geary; Steven M Szczepanek
Journal:  NPJ Vaccines       Date:  2020-04-08       Impact factor: 7.344

10.  Cell surface processing of the P1 adhesin of Mycoplasma pneumoniae identifies novel domains that bind host molecules.

Authors:  Roger Dumke; Steven Philip Djordjevic; Michael Widjaja; Iain James Berry; Veronica Maria Jarocki; Matthew Paul Padula
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.